Aim: To estimate NT-Pro-BNP plasma levels in patients with arterial hypertension (AH) and to find it's correlation with metabolic disorders. Materials and Methods: 148 the Extreme North inhabitants (Noviy Urengoy city) with AH 1–3 stages were examined. Age mediana 49 years (27–60 years) (interquarile range 44.5–51 years). 16.2 % (24) were males, 83.2 (124) – females. Results: In the group of practically healthy people NT-pro-BNP concentration mediana (interquarile range) was 182 (177–217) pg/ml. In the AH 1 stage group of patients NT-pro-BNP level varied significantly, though statistically did not significantly differ -203 (143–288) pg/ml. NT-pro-BNP concentration in patients with AH 2 stage was 348.5 (286–451) pgml, that is statistically higher than in controls (p < 0.001) and in the group of AH 1 stage patients (p < 0.001). AH 3 stage patients had NT-pro-BNP concentration as 345.5 (286–451) pgml, that is statistically higher than in controls (p < 0.001) and in the group of AH 1 stage patients (p < 0.001). The highest Spirman range correlation coefficient was to duration of AH (r = 0,78; p = 0,000003). Then comes very high additional risk (r = 0,58; p = 0,0001), CRP-concentration (r = 0,56; p = 0,0007), number of additional risk factors (r = 0,48; p = 0,003), stage of AH (r = 0,43; p = 0,008), hypercholesterolemia (r = 0,4; p = 0,013), systolic blood pressure level (r = 0,38; p = 0,02), heart disease family anamnesis (r = 0,37; p = 0,02) and TNF-α concentration (r = 0,34; p = 0,03). Conclusion: The main NT-Pro-BNP concentration predictor in serum of AH patients without any heart failure symptoms is AH duration, very high additional risk of cardiovascular complications, and inflammation markers (CRP). NT-Pro-BNP concentration does not depend upon age, sex, body mass excess, though depends on hypercholesterolemia and family history of CVD.